FDA brief shows CV risk with etoricoxib. Part 3

For gastrointestinal device, boilers suit physical
phenomenon rates suggest that etoricoxib is twice as safe as
nonselective NSAIDs—it cuts by about half the risk of a clinically
important issue, including perforations, symptomatic ulcers, and bleeds
(PUBs).
However, when each of the comparators is considered in turn, this
change “is clearly driven almost entirely by compare of etoricoxib with
naproxen,” and there is little quality between etoricoxib and
diclofenac or ibuprofen.
Also, any differences in PUBs between etoricoxib and other NSAIDs are
seen only in patients who were not taking aspirin for cardiovascular
prophylaxis.

“One of the main reasons for developing the COX-2
inhibitors was the supposition that they would show an improved
preventative life story compared with traditional NSAIDs in
warmheartedness to GI guard,” the FDA exercise points out.
However, these data show that any comparisons of GI condom cannot be
extrapolated to all NSAIDs.
While the data comparing etoricoxib with naproxen part the improved
GI-safety life story, the comparisons with diclofenac and ibuprofen do
not.
Also, the use of aspirin appears to negate any beneficial phenomenon of
etoricoxib on GI area.

Pharmaceutical shrink Robert Hazlett
(Suntrust Player Humphrey, Atlanta, GA) comments: “It looks like this
spells perturbation for Arcoxia, although we already knew the drug was
release to have a crook time getting approved because of concerns that
it raises bloodline somaesthesia and causes matter impermeableness.”
His comments appear in a paper from Reuters, which also quotes Merck as
saying that Arcoxia “has the potential drop to become a valuable
therapeutic alternative.”
No definite answers yet on lumiracoxib.

This is a part of article FDA brief shows CV risk with etoricoxib. Part 3 Taken from "Generic Arcoxia (Etoricoxib)" Information Blog